Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 10.92 -8.00% -0.95
BCRX closed down 8.0 percent on Thursday, March 4, 2021, on 1.17 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical BCRX trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Earnings Movers Other 0.00%
Wide Bands Range Expansion 0.00%
Stochastic Reached Overbought Strength -8.00%
Earnings Movers Other -8.00%
Wide Bands Range Expansion -8.00%
Overbought Stochastic Strength -8.00%
Shooting Star Candlestick Bearish -6.98%
NR7 Range Contraction -6.98%
Wide Bands Range Expansion -6.98%
Older End-of-Day Signals for BCRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1 ATR about 7 hours ago
60 Minute Opening Range Breakdown about 7 hours ago
10 DMA Support about 10 hours ago
Down 5% about 10 hours ago
Fell Below 10 DMA about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


BioCryst Pharmaceuticals, Inc. Description

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Diseases Chemical Compounds Influenza Coronavirus Enzymes Viruses Angioedema Drug Design Hereditary Angioedema Medicinal Chemistry Gout Kallikrein Seasonal Influenza Acetamides Crystallography Protease Inhibitor

Is BCRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 12.9
52 Week Low 1.58
Average Volume 6,967,296
200-Day Moving Average 5.74
50-Day Moving Average 9.31
20-Day Moving Average 10.65
10-Day Moving Average 11.34
Average True Range 0.92
ADX 40.75
+DI 29.30
-DI 18.81
Chandelier Exit (Long, 3 ATRs ) 10.15
Chandelier Exit (Short, 3 ATRs ) 11.61
Upper Bollinger Band 12.34
Lower Bollinger Band 8.97
Percent B (%b) 0.58
BandWidth 31.67
MACD Line 0.64
MACD Signal Line 0.66
MACD Histogram -0.02
Fundamentals Value
Market Cap 1.93 Billion
Num Shares 177 Million
EPS -1.15
Price-to-Earnings (P/E) Ratio -9.46
Price-to-Sales 14.96
Price-to-Book 26.95
PEG Ratio -0.28
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.75
Resistance 3 (R3) 12.91 12.46 12.45
Resistance 2 (R2) 12.46 11.99 12.38 12.35
Resistance 1 (R1) 11.69 11.71 11.47 11.53 12.24
Pivot Point 11.24 11.24 11.13 11.16 11.24
Support 1 (S1) 10.47 10.77 10.24 10.31 9.60
Support 2 (S2) 10.02 10.48 9.94 9.49
Support 3 (S3) 9.25 10.02 9.39
Support 4 (S4) 9.09